A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

NCT07557251 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Advanced HBV-Related Hepatocellular Carcinoma

Interventions

DRUG: BRII-5395
DRUG: Sintilimab
DRUG: Bevacizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences